Table 2 Comparison of clinical characteristics of Staphylococcus aureus bacteremia patients based on 30-day mortality

Age (mean [range]) (years)

59.4 [26–85]

66.8 [48–85]

Male

38 (77.6)

8 (80.0)

MRSAB

29 (59.2%)

7 (70.0)

Length of total hospital stay (median [IQR]) (d)

28.0 [20.0–49.0]

14.5 [7.5–35.3]

Duration of bacteremia (median [IQR]) (d)

1.0 [1.0–3.5]

4.5 [1.0–5.3]

Onset of infection

 Community-associated

10 (20.4)

1 (10.0)

 Community-onset, healthcare-associated

17 (34.7)

5 (50.0)

 Hospital-onset

22 (44.9)

4 (40.0)

Location at the time of first positive blood culture

 General ward

20 (40.8)

4 (40.0)

 ICU

3 (6.1)

2 (20.0)

 Emergency room

26 (53.1)

4 (40.0)

CCWI score (median [IQR])

4.0 [1.5–7.0]

6.0 [3.0–8.0]

Pitt bacteremia score (median [IQR])

1.0 [0.0–2.0]

2.0 [1.0–4.0]

SOFA score (median [IQR])

4.0 [1.0–7.0]

7.0 [5.3–9.8]

Severity

 Non-sepsis

7 (14.3)

2 (20.0)

 Sepsis

31 (63.3)

4 (40.0)

 Severe sepsis

6 (12.2)

2 (20.0)

 Septic shock

5 (10.2)

2 (20.0)

Primary site of infection

 Central venous catheter

12 (24.5)

3 (30.0)

 Bone and joint

13 (26.5)

1 (10.0)

 Skin and soft tissue

5 (10.2)

2 (20.0)

 Lower respiratory tract

4 (8.2)

2 (20.0)

 Cardiovascular site^b

8 (16.3)

1 (10.0)

 Unknown

5 (10.2)

1 (10.0)

 Others^c

2 (4.1)

0 (0.0)

Treatment

 Appropriate empirical

35 (71.4)

5 (50.0)

 Appropriate definitive^d

49 (100)

10 (100)

      MRSA

     Vancomycin (n)

34

7

     Linezolid (n)

1

     Fluoroquinolone (n)

1

     MSSA

     Nafcillin (n)

16

3

     Cefazolin (n)

3

      Ampicillin (n)

1

Time until appropriate antibiotic (mean ± SD) (h)

31.0 ± 28.0

28.0 ± 16.4

Persistent SAB

9 (18.4)

5 (50.0)

Metastatic SAB

4 (8.2)

2 (20.0)